Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy
According to the currently available data from large cohort studies, patients with immuno-inflammatory rheumatic diseases (IIRDs) are at increased risk of infectious complications, including influenza, compared to the general population. Vaccinations are a critical component of their care. However,...
| Үндсэн зохиолчид: | , , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | Russian |
| Хэвлэсэн: |
LLC "Publishing House OKI"
2024-06-01
|
| Цуврал: | Антибиотики и Химиотерапия |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.antibiotics-chemotherapy.ru/jour/article/view/1129 |
| _version_ | 1826573456844521472 |
|---|---|
| author | M. M. Baranova N. V. Muravyeva B. S. Belov M. E. Diatroptov D. V. Bukhanova |
| author_facet | M. M. Baranova N. V. Muravyeva B. S. Belov M. E. Diatroptov D. V. Bukhanova |
| author_sort | M. M. Baranova |
| collection | DOAJ |
| description | According to the currently available data from large cohort studies, patients with immuno-inflammatory rheumatic diseases (IIRDs) are at increased risk of infectious complications, including influenza, compared to the general population. Vaccinations are a critical component of their care. However, data on the immunogenicity, efficacy, and safety of influenza vaccines in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) receiving modern anti-rheumatic drugs are limited.The aim of the study was to investigate the immunogenicity, efficacy, and safety of the trivalent inactivated influenza split vaccine in patients with RA, AS and PsA, observed at the V. A. Nasonova Research Institute.Materials and methods. The open prospective comparative study included 247 patients: 74 patients with RA, 62 patients with AS, 14 patients with PsA, as well as 97 people without IIRDs who comprised the control group (СG). The patients were selected over six epidemic seasons: 2016–2017, 2017–2018, 2018–2019, 2020–2021, 2021–2022, and 2022–2023. The majority of patients (78,7%) received immunosuppressive therapy at the time of inclusion in the study. The trivalent inactivated influenza split vaccine was administered in an amount of 1 dose (0,5 ml) intramuscularly against the background of anti-rheumatic therapy, regardless of the activity of the main IIRD. The level of class G antibodies to hemagglutinin (HA) of influenza A (H1N1), A (H3N2), and B viruses was determined in optical density units (OD units) using an enzyme-linked immunosorbent assay (PPDP LLC, St. Petersburg) before vaccination, 1–3 and 6 months after vaccination. The clinical efficacy and safety of the trivalent inactivated influenza split vaccine were also evaluated, including the effect on the course of RA, AS, and PsA according to the dynamics of disease activity indices.Results. After vaccination, a significant increase in the level of antibodies was observed in patients with RA, AS, and PsA. At the second visit after vaccination the level of antibodies, determined in units of optical density, to HA of influenza A (H1N1), A (H3N2) and B was significantly higher compared to baseline values. By the third visit (6 months after vaccination), there was a slight decrease in the immune response, but the level of antibodies remained significantly higher than the initial level for all strains of influenza virus, with the exception of influenza B in the group of patients with RA. During follow-up, influenza or influenza-like illness was absent in 98,6% of patients who completed the study. No negative effect of vaccination on the activity of the underlying IIRD was noted. The frequency of post-vaccination reactions in patients with IIRDs and in the СG was comparable.Conclusions. The results obtained in the study indicate sufficient immunogenicity, clinical efficacy, and safety of the trivalent inactivated influenza split vaccine in patients with RA, AS, and PsA. |
| first_indexed | 2025-03-14T12:43:12Z |
| format | Article |
| id | doaj.art-f9554b5a7b7942a88a7384c4cb15b47d |
| institution | Directory Open Access Journal |
| issn | 0235-2990 |
| language | Russian |
| last_indexed | 2025-03-14T12:43:12Z |
| publishDate | 2024-06-01 |
| publisher | LLC "Publishing House OKI" |
| record_format | Article |
| series | Антибиотики и Химиотерапия |
| spelling | doaj.art-f9554b5a7b7942a88a7384c4cb15b47d2025-03-02T09:09:23ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902024-06-01693-49510110.37489/0235-2990-2024-69-3-4-95-1011034Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic TherapyM. M. Baranova0N. V. Muravyeva1B. S. Belov2M. E. Diatroptov3D. V. Bukhanova4V. A. Nasonova Research Institute of RheumatologyV. A. Nasonova Research Institute of RheumatologyV. A. Nasonova Research Institute of RheumatologyV. A. Nasonova Research Institute of RheumatologyJSC R-PHARMAccording to the currently available data from large cohort studies, patients with immuno-inflammatory rheumatic diseases (IIRDs) are at increased risk of infectious complications, including influenza, compared to the general population. Vaccinations are a critical component of their care. However, data on the immunogenicity, efficacy, and safety of influenza vaccines in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) receiving modern anti-rheumatic drugs are limited.The aim of the study was to investigate the immunogenicity, efficacy, and safety of the trivalent inactivated influenza split vaccine in patients with RA, AS and PsA, observed at the V. A. Nasonova Research Institute.Materials and methods. The open prospective comparative study included 247 patients: 74 patients with RA, 62 patients with AS, 14 patients with PsA, as well as 97 people without IIRDs who comprised the control group (СG). The patients were selected over six epidemic seasons: 2016–2017, 2017–2018, 2018–2019, 2020–2021, 2021–2022, and 2022–2023. The majority of patients (78,7%) received immunosuppressive therapy at the time of inclusion in the study. The trivalent inactivated influenza split vaccine was administered in an amount of 1 dose (0,5 ml) intramuscularly against the background of anti-rheumatic therapy, regardless of the activity of the main IIRD. The level of class G antibodies to hemagglutinin (HA) of influenza A (H1N1), A (H3N2), and B viruses was determined in optical density units (OD units) using an enzyme-linked immunosorbent assay (PPDP LLC, St. Petersburg) before vaccination, 1–3 and 6 months after vaccination. The clinical efficacy and safety of the trivalent inactivated influenza split vaccine were also evaluated, including the effect on the course of RA, AS, and PsA according to the dynamics of disease activity indices.Results. After vaccination, a significant increase in the level of antibodies was observed in patients with RA, AS, and PsA. At the second visit after vaccination the level of antibodies, determined in units of optical density, to HA of influenza A (H1N1), A (H3N2) and B was significantly higher compared to baseline values. By the third visit (6 months after vaccination), there was a slight decrease in the immune response, but the level of antibodies remained significantly higher than the initial level for all strains of influenza virus, with the exception of influenza B in the group of patients with RA. During follow-up, influenza or influenza-like illness was absent in 98,6% of patients who completed the study. No negative effect of vaccination on the activity of the underlying IIRD was noted. The frequency of post-vaccination reactions in patients with IIRDs and in the СG was comparable.Conclusions. The results obtained in the study indicate sufficient immunogenicity, clinical efficacy, and safety of the trivalent inactivated influenza split vaccine in patients with RA, AS, and PsA.https://www.antibiotics-chemotherapy.ru/jour/article/view/1129influenzarheumatoid arthritisankylosing spondylitispsoriatic arthritisvaccinationefficacyimmunogenicitysafety |
| spellingShingle | M. M. Baranova N. V. Muravyeva B. S. Belov M. E. Diatroptov D. V. Bukhanova Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy Антибиотики и Химиотерапия influenza rheumatoid arthritis ankylosing spondylitis psoriatic arthritis vaccination efficacy immunogenicity safety |
| title | Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy |
| title_full | Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy |
| title_fullStr | Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy |
| title_full_unstemmed | Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy |
| title_short | Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy |
| title_sort | immunogenicity effectiveness and safety of trivalent inactivated influenza split vaccine in patients with inflammatory joint diseases receiving modern antirheumatic therapy |
| topic | influenza rheumatoid arthritis ankylosing spondylitis psoriatic arthritis vaccination efficacy immunogenicity safety |
| url | https://www.antibiotics-chemotherapy.ru/jour/article/view/1129 |
| work_keys_str_mv | AT mmbaranova immunogenicityeffectivenessandsafetyoftrivalentinactivatedinfluenzasplitvaccineinpatientswithinflammatoryjointdiseasesreceivingmodernantirheumatictherapy AT nvmuravyeva immunogenicityeffectivenessandsafetyoftrivalentinactivatedinfluenzasplitvaccineinpatientswithinflammatoryjointdiseasesreceivingmodernantirheumatictherapy AT bsbelov immunogenicityeffectivenessandsafetyoftrivalentinactivatedinfluenzasplitvaccineinpatientswithinflammatoryjointdiseasesreceivingmodernantirheumatictherapy AT mediatroptov immunogenicityeffectivenessandsafetyoftrivalentinactivatedinfluenzasplitvaccineinpatientswithinflammatoryjointdiseasesreceivingmodernantirheumatictherapy AT dvbukhanova immunogenicityeffectivenessandsafetyoftrivalentinactivatedinfluenzasplitvaccineinpatientswithinflammatoryjointdiseasesreceivingmodernantirheumatictherapy |